帕金森病中多巴胺能神经元的突触和非突触成分之间的生物能差异的基于约束的建模
Xi Luo1, Diana C El Assal2, Yanjun Liu1
1School of Medicine, University of Galway, Galway, Ireland.
Frontiers in computational neuroscience
|June 20, 2025
概括
突触终端和 soma 的代谢差异有助于帕金森病 (PD) 的脆弱性. 准线粒体甲状腺氨酸酶可能通过恢复神经元能量平衡为PD提供治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 系统生物学 系统生物学
- 代谢工程是代谢工程.
背景情况:
- 在帕金森病 (PD) 中,多巴胺基神经元的脆弱性可能源于突触终端和体域之间的明显代谢特征.
- 了解这些生物能量差异对于识别PD病原机制至关重要.
研究的目的:
- 在受控和PD条件下的多巴胺基神经元中,研究突触和体内区间之间的代谢和生物能量差异.
- 确定潜在的治疗点,以减轻帕金森病中的代谢功能障碍.
主要方法:
- 为突触和体质组分 (控制和PD) 创建四个热力学流量一致的代谢模型.
- 对生物能特征和代谢物交换的分析.
- 生物能量救援分析以确定治疗点.
主要成果:
- 模型根据能源需求预测了氧化酸化和糖解的不同作用.
- 突触性PD模型显示线粒体能量贡献较低,对复合I抑制的敏感性更高.
- 预测特定代谢物 (lysine,乳酸盐,氨酸,尿素,histidine,甘油酸) 的摄入量减少,因区域而异.
- 预计通过线粒体甲状腺氨酸酶 (ORNTArm) 增加的流量将在突触和体质PD模型中拯救生物能衰竭.
结论:
- 预测的生物能量和代谢物交换差异突显了PD的分区脆弱性.
- 线粒体的甲状腺氨酸转氨酶成为PD中突触和体内两部分的潜在治疗点.
- 需要进一步验证,以探索针对帕金森病的向治疗策略.
相关概念视频
01:37Neural Regulation
40.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.4K
01:15Parkinson's Disease: Overview
722
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
722
01:24Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
01:29Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
01:29Excitatory and Inhibitory Effects of Neurotransmitters
10.8K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
10.8K